Citigroup
ALDX icon

Citigroup’s Aldeyra Therapeutics ALDX Stock Holding History

Citigroup’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-800
Closed -$3K – 5788
2022
Q2 		$3K Hold
800
– – ﹤0.01% 5758
2022
Q1 		$4K Sell
800
-79,200
-99% -$315K ﹤0.01% 5872
2021
Q4 		$320K Buy
+80,000
New +$610K ﹤0.01% 4078

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citigroup's ALDX Position: Q1 2026 in Review

Citigroup increased its Aldeyra Therapeutics (ALDX) stake by 100% in Q1 2026, buying an estimated $6.82K and bringing the position to 3,111 shares worth $5.26K. The position accounts for ﹤0.01% of the portfolio, ranked #5253.

Citigroup first reported a position in ALDX in Q3 2014 and has held it in 34 quarters since. The position peaked at $14.1M in Q3 2018. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Citigroup held 3,111 shares of Aldeyra Therapeutics worth $5.26K as of Q1 2026.
  • Citigroup bought 1,556 Aldeyra Therapeutics shares in Q1 2026, an estimated $6.82K.
  • Aldeyra Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5253 holding.
  • Citigroup first reported a position in Aldeyra Therapeutics in Q3 2014 and has held it in 34 quarters since.
  • Citigroup's Aldeyra Therapeutics position peaked at $14.1M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.